- €49.21bn
- €48.90bn
- €7.74bn
Europe Research Roundup: Diageo, Roche Holding, Vaisala
Jefferies downgrades UCB on Bimzelx slowdown
Europe Research Roundup: Fluidra, Klepierre, Tate & Lyle
Europe Research Roundup: Banco BPM, DWS Group, UCB
Refile: BUZZ-'Overall a relief': TrumpRx price cuts deals boost European pharma stocks
MoonLake Immunotherapeutics plunges after disappointing data from key skin drug trials
Live Markets: FTSE edges toward record as healthcare stocks surge
UCB at record high after competitor's skin disease drug data
European pharma stocks largely steady amid new US tariff onslaught
Brief: UCB: Successful First-In-Patient Trial For Galvokimig In Moderate-To-Severe Atopic Dermatitis
Brief: UCB Releases Bimekizumab New Three-Year Data In Hidradenitis Suppurativa At EADV
Brief: UCB Says Bimekizumab Data In Plaque Psoriasis At EADV Showed Four-Year Sustained Remission
Europe Research Roundup: Bioinvent, Diasorin, Sandoz
Europe Research Roundup: Alfen, Argenx, JDE Peet's
UCB jumps to record high on H1 beat, outlook hike
Brief: UCB Revenue In First Half Of 2025 Increased To EUR 3.49 Billion
GS starts UCB with 'buy' on skin disease drug potential
European pharmaceuticals fall on looming U.S. tariffs
Brief: UCB Announces Positive Results From Gemz Phase 3 Study Of Fenfluramine In Cdkl5 Deficiency Disorder